Methods of preparing chiral benzodiazepinone derivatives
Inventors
Cimarusti, Christopher M. • LAHOTI, Anandkumar Madanlal • DARAM, Madan Raja Gopal Reddy
Assignees
Pharmaceutical Advisors LLC • Neuland Laboratories Ltd • Immunome Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently identical or different C1-C5 alkyl; n1 is an integer between 1 and 5; and n2 is an integer between 1 and 4. In addition, the present invention provides a compound represented by the following structures: Compound (1a) and Compound (2), wherein X comprises: chloride, acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydroiodide, maleate, 2-hydroxyethanesulfonate, lactate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, or undecanoate salt, or any combination thereof.
Core Innovation
The invention relates to chiral benzodiazepinone derivatives defined by Formula (I), including variants in which R1 is independently Cl, F, Br, I, OCH3, CN or NO2, R2 is an independently identical or different C1-C5 alkyl, n1 is an integer between 1 and 5, and n2 is an integer between 1 and 4. Specific embodiments are exemplified, including Compound (1a), Compound (2), and salt forms derived from these structures.
The invention relates to methods of preparing compounds of Formula (Ib) or (Id) by reacting a compound of Formula (Ia) with L-pyroglutamic acid (L-PGA) or D-pyroglutamic acid (D-PGA), respectively, in the presence of solvent and with or without catalyst. In further preparation, compounds of Formula (Ic) are obtained by reacting a compound of Formula (Ib) with base and solvent to provide a compound of Formula (I), followed by reaction with S-(+) camphor sulfonic acid (CSA) to provide a compound of Formula (Ic).
The disclosure also defines compounds using a specific structural representation and limits a salt-related parameter X. X comprises selected anions and salt forms including chloride, acetate, alginate, ascorbate, aspartate, benzoate, camphorate, camphorsulfonate, citrate, lactate, maleate, nitrate, oxalate, phosphate, picrate, propionate, salicylate, succinate, sulfate, sulfonate, tartrate, thiocyanate, toluenesulfonate, undecanoate salt, and any combination thereof.
Claims Coverage
The partial content shows three independent claims: one method claim for preparing compounds of Formula (Ib) or (Id), a second method claim for preparing compounds of Formula (Ic) via Formula (I), and a third compound claim defining salt forms through a structure with X comprising selected anion or salt types. Across these independent claims, the main inventive features are the pyroglutamic acid reaction, the base and CSA conversion sequence, and the defined salt-form selection for X.
Pyroglutamic acid reaction to obtain Formula (Ib) or (Id)
A method of preparing the compound of Formula (Ib) or (Id) by reacting the compound of Formula (Ia) with L-pyroglutamic acid (L-PGA) or D-pyroglutamic acid (D-PGA), respectively, in the presence of solvent and with or without catalyst.
Base to form Formula (I) and S (+) camphor sulfonic acid to obtain Formula (Ic)
A method of preparing the compound of Formula (Ic) by reacting the compound of Formula (Ib) with a base and solvent to provide a compound of Formula (I), and reacting the compound of Formula (I) with S (+) camphor sulfonic acid (CSA) to provide a compound of Formula (Ic).
Salt-form selection for a structurally defined compound via X
A compound represented by a specified structure wherein X comprises selected salt forms including chloride and a listed set of anions or salts, where X comprises one or more of the listed types or any combination thereof.
Overall, the independent claims cover converting Formula (Ia) to Formula (Ib)/(Id) using L- or D-pyroglutamic acid, generating Formula (Ic) through a base and solvent step to Formula (I) followed by reaction with S (+) CSA, and defining acceptable salt forms for a structurally defined compound via the parameter X with a specified list of anions or salts.
Stated Advantages
Produces compounds with chiral purity greater than 99%.
Produces compounds with chiral purity greater than 99.5%.
Produces compounds with yield greater than 50%.
Improved yields for Compound (1b) are described in the disclosure supporting PGA-based preparation.
Resolution is described as enabled by D- and L-pyroglutamic acid salt formation, while comparative non-PGA salt formation is described as lacking resolution.
High chiral purity is reported in the disclosure, including 99.88% and chiral HPLC values during scale-up.
Documented Applications
Preparation of specific salt forms, including enantiomeric chiral salts formed using L/D-pyroglutamic acid and S-(+) CSA salts, and preparation of compounds identified as Compounds (1), (1d), and (1c) with reported chiral purity outcomes.
Preparation and resolution of target compounds represented by Compound (1b) (Formula (Ib)), Compound (1d) (Formula (Id)), and Compound (1c) (Formula (Ic)) are documented through PGA-based steps and CSA derivatization within the disclosed supporting examples.
A dynamic kinetic resolution study concept is described using specific aldehyde catalysts and solvent systems.
Interested in licensing this patent?